Agenus Announces U.S. FDA Acceptance and Priority Review of Balstilimab Biologics License Application for the Treatment of Recurrent or Metastatic Cervical Cancer

Source :: Legal Monitor Worldwide. June 18, 2021
Publication Year :: 2021
Abstract: (GlobeNewswire) - Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents which includes checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to [...]

Subjects :: United States. Food and Drug Administration
Biopharmaceutics
Cancer -- Adjuvant treatment
Metastasis
Diseases -- Relapse
Viral antibodies
Cervical cancer
Drug approval
Vaccines
Antibodies
Business, international
Law

Tools